- Case report
- Open Access
- Open Peer Review
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report
© Rivera et al; licensee BioMed Central Ltd. 2010
- Received: 31 December 2008
- Accepted: 11 February 2010
- Published: 11 February 2010
Henoch-Schönlein purpura is a systemic disease with frequent renal involvement, characterized by IgA mesangial deposits. Streptococcal infection can induce an abnormal IgA immune response like Henoch-Schönlein purpura, quite similar to typical acute post-infectious glomerulonephritis. Indeed, hypocomplementemia that is typical of acute glomerulonephritis has also been described in Henoch-Schönlein purpura.
We describe a 14-year-old Caucasian Spanish girl who developed urinary abnormalities and cutaneous purpura after streptococcal infection. Renal biopsy showed typical findings from Henoch-Schönlein purpura nephritis. In addition, she had low serum levels of complement (C4 fraction) that persisted during follow-up, in spite of her clinical evolution. She responded to treatment with enalapril and steroids.
The case described has, at least, three points of interest in Henoch-Schönlein purpura: 1) Initial presentation was preceded by streptococcal infection; 2) There was a persistence of low serum levels of complement; and 3) There was response to steroids and angiotensin-converting enzyme inhibitor in the presence of nephrotic syndrome. There are not many cases described in the literature with these characteristics. We conclude that Henoch-Schönlein purpura could appear after streptococcal infection in patients with abnormal complement levels, and that steroids and angiotensin-converting enzyme inhibitor could be successful treatment for the disease.
- Nephrotic Syndrome
- Renal Biopsy
- Angiotensin Converting Enzyme Inhibitor
Henoch-Schönlein purpura (HSP) is a systemic disease with frequent renal involvement, characterized by IgA mesangial deposits. Its etiology is unknown, but several infections have been described as trigger agents . Streptococcal infection could induce an abnormal IgA immune responses like HSP, quite similar to typical acute post-infectious glomerulonephritis (AGN) [2, 3]. Indeed, hypocomplemetemia that is typical of AGN has been also described in HSP .
We describe a young girl patient who developed urinary abnormalities and cutaneous purpura after streptococcal infection. Renal biopsy showed findings typical of HSP nephritis, with prominent mesangial IgA deposits. In addition, she had low serum levels of C4 that persist during follow-up, in spite of her clinical evolution. We conclude that HSP can appear after streptococcal infection in patients with abnormal complement levels.
A 14-year-old Caucasian Spanish girl without previous diseases or known renal diseases, had an upper respiratory tract infection in December 2007 with malaise, no cough, tonsilar swelling, sore throat and fever >38°C, which were treated with codeine and acetaminophen. Four weeks later, she developed arthralgias and asthenia followed by purpura on legs, arms and abdomen. There was no abdominal pain or oedema. During physical examination, blood pressure was 100/45 mmHg and she did not have oedemas; she presented palpable purpura. Urine analysis revealed microscopic haematuria, proteinuria (ratio protein/creatinine 3.4 mg/mg) and granular casts with normal renal function (serum creatinine 0.8 mg/dl). Some other laboratory findings were: haemoglobin 12.7 g/dl, white cell count 6300 μ, platelet count 226000 μl, antistreptolisin-O 465 U/ml (normal under 240), serum total proteins 6 g/dL and albumin 3.7 g/dL. Coagulation study was not altered. ANA, anti-DNA, ANCAS, antibodies anti-MBG, crioglobulins, lupus anticogalulant and anticardiolipin antibodies were negatives. IgG 969 mg/dl, IgA 150 mg/dl, IgM 93 mg/dl. C3 87 mg/dl and C4 low (13 mg/dl, normal interval 15-45).
The case described has, at least, three points of interest in HSP: 1) Initial presentation was preceded by streptococcal infection; 2) There was persistence of low serum levels of C4; and 3) There was response to steroids and angiotensin converting enzyme inhibitor (ACEI) in the presence of nephrotic syndrome. We are going to discuss these points in the following paragraphs.
Both AGN and HSP nephritis could appear after antigen exposure with similar clinical presentation such hematuria, edemas and hypertension [2, 5, 6]. In this case, streptococcus infection was supported by clinical data and high serum ASLO levels that decreased subsequently. Moreover, the clinical picture and the absence of diabetes or other debilitating diseases indicates that the presence of staphyloccocus infection-associated glomerulonephritis mimicking IgA nephropathy seems unlikely . On the one hand, the presence of hypocomplementemia would make AGN to be a more likely diagnosis. Although in this GN the complement system is usually activated by alternative pathway, it has been described as the activation by classical pathway, characterized by low levels of C4 without decrease of C3, as we observed in our patient. Moreover, GNA has also been described as having the presence of systemic vasculitis affecting skin, bowel and other organs mimicking HSP [5, 6]. On the other hand, the presence of purpura and absence of typical nephritic syndrome supported the diagnosis of HSP. Indeed, it has been also described that ASLO titer positivity is associated with a significant increase in the risk of HSP and renal involvement is more common among cases with positive elevated titers .
Finally, renal biopsy was essential to establish definitive diagnosis, as occured in many glomerular diseases. The presence of mesangial proliferation without leukocyte infiltration and the presence of IgA deposits led us to a definitive diagnosis of HSP. These findings remark the importance of renal biopsy in the diagnosis of the majority of glomerular diseases because clinical manifestations may be similar in many different glomerular diseases . We think that our patient did not have superimposed minimal change disease, although it is impossible to ensure since we did not do an electronic microscopy study. However, if the biopsy of our patient had podocyte fusion, it would explain by nephrotic proteinuria as an unspecific finding.
Although there are no serum markers of HSP, the increase of serum IgA in more than 50% of patients without modification of complement serum levels has been found . However, in some patients with HSP nephritis transient hypocomplemetemia may appear . Indeed, congenital defects of complement fractions are recognized predisposing factors in the development of other systemic diseases such as lupus erythematosus, Sjögren and connective tissue diseases. Furthermore, several authors have described in HSP the presence of low C4 serum levels in acute phase of nephritis in 17%, and about 20% in chronic evolution. This hypocomplemetemia is not related to the severity of the disease in most of patients .
In our case, the low C4 levels did not have any relation with the severity of renal evolution. Whether the hypocomplementemia is the result of complement activation after immunological activation from immune complex or indicates a congenital defect is difficult to clarify. In our case, the presence of low serum levels of C4, irrespective of clinical evolution, allows us to consider a congenital deficit because when nephropathy reached complete remission, the levels of serum C4 remained low.
Recently, it has been described that C4 null alleles were significantly more common among HSP patients than in controls and so children with C4 deficiencies may have increased risk of developing HSP . Furthermore, the C4 congenital deficit is the most frequent complement congenital deficit, which in many occasions has no clinical consequences. However, in patients with other immunological alterations such abnormal IgA1 O-glycosilation , the infection with streptococcal antigens -or other antigenic stimuli- could trigger the development of HSP nephritis, as we observed in our case.
On the other hand, the so called "Nephritis-Associated-Plasmin-Receptor" (NAPlr) which has been found in the glomeruli and in sera of many patients with AGN [13, 14] has been also found in renal glomeruli in 10/33 of patients with PSH and it is likely that the deposition of NAPlr in the mesangium may have a role in the pathogenesis of HSP ; and this antigen may be related to the pathogenesis in some patients with SHP . It is attractive to speculate about streptococcal infection being involved in both GN, with the participation of NAPlr antigen. In our case, we can speculate that streptococcal infection in a patient with abnormal IgA response and congenital complement abnormalities derives from the development of HSP nephritis.
The treatment of HSP is controversial and the use of steroids and immunosuppressive drugs must be reserved for cases with a severe form of presentation. Corticosteroids produce consistent benefits and reduce the odds of developing persistent renal disease . In our case, the development of nephrotic syndrome allows us to start treatment with steroids and the evolution was quite good. In our patient, we added a low dose of enalapril as an antiproteinuric measure, despite our patient having a completely normal blood pressure because of the well demonstrated beneficial effect of ACEI in idiopathic IgA nephropathy . Therefore, the use of ACEI would certainly influence its evolution.
We conclude that HSP could appear after streptococcal infection in patients with abnormal complement levels and irreversible glomerular injury could be prevented if treatment with steroids were initiated early.
Written informed consent was obtained from the parents of our patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Prof Bernardo Rodriguez-Iturbe has made substantial contributions to the elaboration of the manuscript and his advice has improved our understanding of many aspects of the case described.
This Case Report has been discussed in the 15th Meeting of Spanish Nephropathology Club, held in Madrid, 2008.
- Dedeoglu F, Kim S, Sundel R: Clinical manifestations and diagnosis of Henoch-Schönlein purpura. Edited by: Basow DS. 2008, Waltham MA: UpToDateGoogle Scholar
- Al-Ruqeishi N, Venugopalan P, El Nour I, Date A: IgA nephropathy presenting clinical features of poststreptococcal glomerulonephritis. Pediatr Nephrol. 2003, 18: 956-958. 10.1007/s00467-003-1212-3.View ArticlePubMedGoogle Scholar
- Rodriguez-Iturbe B, Musser JM: The Current State of Poststreptococcal Glomerulonephritis. JASN. 2008, 19: 1855-1864.View ArticlePubMedGoogle Scholar
- Motoyama O, Iitaka K: Henoch-Schönlein purpura with hypocomplementemia in children. Pediatr Int. 2005, 47: 39-42. 10.1111/j.1442-200x.2005.02005.x.View ArticlePubMedGoogle Scholar
- Goodyer PR, de Chadarevian JP, Kaplan BS: Acute poststrepotococcal glomerulonephritis mimicking Henoch-Schönlein purpura. J Pediatr. 1978, 93: 412-415. 10.1016/S0022-3476(78)81147-0.View ArticlePubMedGoogle Scholar
- Matsukura H, Ohtsuki A, Fuchizawa T, Miyawaki T: Acute poststreptococcal glomerulonephritis mimicking Henoch-Schönlein purpura. Clin Nephrol. 2003, 59: 64-65.View ArticlePubMedGoogle Scholar
- Satoskar AA, Nadasdy G, Plaza JA, Sedmak D, Shidham G, Hebert L, Nadasdy T: Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol. 2006, 1: 1179-1186. 10.2215/CJN.01030306.View ArticlePubMedGoogle Scholar
- Al-Sheyyab M, Batieha A, El-Shanti H, Daoud A: Henoch-Schönlein purpura and streptococcal infection: a prospective case-control study. Ann Trop Paediatr. 1999, 19: 253-255. 10.1080/02724939992329.View ArticlePubMedGoogle Scholar
- Rivera F, López-Gómez JM, Pérez García R: Clinicopathological correlations of renal pathology in Spain. Kidney Int. 2004, 66: 898-904. 10.1111/j.1523-1755.2004.00833.x.View ArticlePubMedGoogle Scholar
- Smith GC, Davidson JE, Hughes DA, Holme E, Beattie TJ: Complement activation in Henoch-Schönlein purpura. Pediatr Nephrol. 1997, 11: 477-480. 10.1007/s004670050320.View ArticlePubMedGoogle Scholar
- Stefansson Thors V, Kolka R, Sigurdardottir SL, Edvardsson VO, Arason G, Haraldsson A: Increased frequency of C4B*Q0 alleles in patients with Henoch-Schönlein purpura. Scand J Immunol. 2005, 61: 274-278. 10.1111/j.1365-3083.2005.01533.x.View ArticlePubMedGoogle Scholar
- Allen AC, Willis FR, Beattie TJ, Feehally J: Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998, 13: 930-934. 10.1093/ndt/13.4.930.View ArticlePubMedGoogle Scholar
- Yamakami K, Yoshizawa N, Wakabayashi K, Takeuchi A, Tadakuma T, Boyle MDP: The potencial Role for Nephritis-Associated Plasmin Receptor in Acute poststreptococcal Glomerolonephritis. Methods. 2000, 21: 185-197. 10.1006/meth.2000.0990.View ArticlePubMedGoogle Scholar
- Yoshizawa N, Yamakami K, Fujino M, Oda T, Tamura K, Tsumoto K, Sugisaki T, Boyle MDP: Nephritis-Associated Plasmin Receptor and Acute Poststreptococcal Glomerulonephritis: Characterization of the Antigen and Associated Immune Response. J Am Soc Nephrol. 2004, 15: 1785-1793. 10.1097/01.ASN.0000130624.94920.6B.View ArticlePubMedGoogle Scholar
- Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N: Group A Streptococcal Antigen in the Glomeruli of Children with Henoch-Schönlein Nephritis. Am J Kidney Dis. 2003, 41: 366-370. 10.1053/ajkd.2003.50045.View ArticlePubMedGoogle Scholar
- Kikuchi Y, Yoshizawa N, Oda T, Imakiire T, Suzuki S, Miura S: Streptococcal origin of a case of Henoch-Schoenlein purpura nephritis. Clin Nephrol. 2006, 65: 124-128.View ArticlePubMedGoogle Scholar
- Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C: Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007, 120: 1079-1087. 10.1542/peds.2007-0667.View ArticlePubMedPubMed CentralGoogle Scholar
- Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003, 14: 1578-1583. 10.1097/01.ASN.0000068460.37369.DC.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.